Format

Send to

Choose Destination
Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.

Revisiting 5α-reductase inhibitors and the risk of prostate cancer.

Author information

1
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. figgw@helix.nih.gov.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center